Anti-CD20 therapy for the treatment of chronic graft versus host disease.

Trial Profile

Anti-CD20 therapy for the treatment of chronic graft versus host disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 May 2009 Additional lead trial centres reported by Netherlands Trial Register.
    • 02 May 2009 Planned end date changed from 1 Jul 2008 to 1 Nov 2010 as reported by Netherlands Trial Register.
    • 02 May 2009 New source identified and integrated (Netherlands Trial Register NTR1222).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top